Bülent YILDIZ, Deniz ARIK, Güneş Deniz YILDIRIM, Özgül PAŞAOĞLU, Necdet Fatih YAŞAR, Murat DİNÇER

High nucleostemin expression has a favorable prognostic effect on gastric carcinomas

Background/aim: Nucleostemin is a nuclear protein that maintains stem cell features and plays a role as a cell proliferation marker. Italso participates in cell cycle regulation by interfering with other intracellular proteins. Recent reports have indicated that this proteinplays a role in ribosomal biogenesis and genome protection. High expression level of nucleostemin has been reported in some cancerpatients. However, the importance of nucleostemin in gastric cancer needs to be addressed. The aim of this study was to investigatenucleostemin expression in gastric cancer and the effects of this expression on prognosis.Materials and methods: Nucleostemin expression was assessed in 103 patients with gastric carcinomas via immunohistochemistry.Subsequently, relationships between nucleostemin expression and clinicopathological features and prognosis were evaluated.Results: In this study, there were 33 and 70 cases involving high and low nucleostemin expression, respectively. Nucleostemin expressionwas negatively correlated with lymphovascular invasion, the number of metastatic lymph nodes, extracapsular extension, and T stage.Disease-free survival and overall survival were markedly longer in patients with high nucleostemin expression.Conclusion: We suggest that nucleostemin is a favorable prognostic marker for gastric cancer patients. Our results are in conflict withprior studies. The prognostic effect of nucleostemin in gastric cancer remains to be solved.

PDF

___

Torre A, Bray F, Siegel L, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA-Cancer J Clin 2015; 65: 87- 108.
Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World Journal of Gastrointestinal Oncology 2012; 4: 156-169.
Tsai RY, McKay RD. Nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Gene Dev 2002; 16: 2991-3003.
Romanova L, Kellner S, Katoku-Kikyo N, Kikyo N. Novel role of nucleostemin in the maintenance of nucleolar architecture and integrity of small nucleolar ribonucleoproteins and the telomerase complex. J Biol Chem 2009; 284: 26685-26694.
Beekman C, Nichane M, De Clercq S, Maetens M, Floss T, Wurst W, Bellefroid E, Marine JC. Evolutionary conserved role of nucleostemin: controlling proliferation of stem/progenitor cells during early vertebrate development. Mol Cell Biol 2006; 26: 9291-9301.
Tsai RY, McKay RD. A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J Cell Biol 2005; 168: 179-184.
Ma H, Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 2007; 18: 2630-2635.
Hsu JK, Lin T, Tsai RY. Nucleostemin prevents telomere damage by promoting PML-IV recruitment to SUMOylated TRF1. J Cell Biol 2012; 197: 613-624.
Uema N, Ooshio T, Harada K, Naito M, Naka K, Hoshii T, Tadokoro Y, Ohta K, Ali MA, Katano M et al. Abundant nucleostemin expression supports the undifferentiated properties of germ cell tumors. Am J Pathol 2013; 183: 592- 603.
Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008; 28: 4365-4376.
Meng L, Lin T, Peng G, Hsu JK, Lee S, Lin SY, Tsai RY. Nucleostemin deletion reveals an essential mechanism that maintains the genomic stability of stem and progenitor cells. P Natl Acad Sci USA 2013; 110: 11415-11420.
Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008; 8: 108.
Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K. Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. Cancer Sci 2012; 103: 233-238.
Fan Y, Liu Z, Zhao S, Lou F, Nilsson S, Ekman P, Xu D, Fang X. Nucleostemin mRNA is expressed in both normal and malignant renal tissues. Brit J Cancer 2006; 94: 1658-1662.
Liu RL, Zhang ZH, Zhao WM, Wang M, Qi SY, Li J, Zhang Y, Li SZ, Xu Y. Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. Chinese Med J-Peking 2008; 121: 299-304.
Kobayashi T, Masutomi K, Tamura K, Moriya T, Yamasaki T, Fujiwara Y, Takahashi S, Yamamoto J, Tsuda H. Nucleostemin expression in invasive breast cancer. BMC Cancer 2014; 14: 215.
Liu SJ, Cai ZW, Liu YJ, Dong MY, Sun LQ, Hu GF, Wei YY, Lao WD. Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J Gastroentero 2004; 10: 1246-1249.
Li X, Liu X, Cui D, Wu X, Qian R. Clinical significance of nucleostemin and proliferating cell nuclear antigen protein expression in non-small cell lung cancer. J BUON 2015; 20: 1088-1093.
Yoshida R, Nakayama H, Nagata M, Hirosue A, Tanaka T, Kawahara K, Nakagawa Y, Matsuoka Y, Sakata J, Arita H et al. Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma. Brit J Cancer 2014; 111: 2308-2315.
Asadi MH, Derakhshani A, Mowla SJ. Concomitant upregulation of nucleostemin and downregulation of Sox2 and Klf4 in gastric adenocarcinoma. Tumor Biol 2014; 35: 7177- 7185.
Wu H, Wang W, Tong S, Wu C. Nucleostemin regulates proliferation and migration of gastric cancer and correlates with its malignancy. Int J Clin Exp Med 2015; 8: 17634-17343.
Tsai RY, Meng L. Nucleostemin: a latecomer with new tricks. Int J Biochem Cell B 2009; 41: 2122-2124.
Huang G, Meng L, Tsai RY. p53 configures the G2/M arrest response of nucleostemin-deficient cells. Cell Death Discovery 2015; 1: 15060.
Lo D, Zhang Y, Dai MS, Sun XX, Zeng SX, Lu H. Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF. Oncogene 2015; 34: 1688-1697.
Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009; 16: 369-377.
Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6: 663-673.
Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer 2002; 2: 594-604.